Introduction
The introduction is well written. I have no additional comments.
Study hypotheses 1. The authors mention that this is a proof-of-concept (PoC) study that test the feasibility and acceptability of the design. However, the main study hypotheses (as well as outcomes) focus on the efficacy of the intervention under investigation. I recommend that the authors include additional hypotheses/outcomes that take feasibility/acceptability into account.
Clinical Assessments 1. The choice of primary outcomes is reasonable. However, considering the IMMPACT guidelines (e.g., Cooper et al. [2016] . Research design considerations for single-dose analgesic clinical trials in acute pain: IMMPACT recommendations. Pain, 157(2), 288-301), I recommend that emotional distress (and not only functional disability) should be included as an additional outcome.
In line with IMMPACT, the so-called "extension code" for pain severity in the new ICD-11 allows to not only measure pain intensity, yet also pain-related interference and pain-related distress) on an NRS scale.
Outcome measures 1. How will the rate of opioids (frequency and dosage) be measured? I recommend that the author specify whether this is based on self-report, on observation, or whether trackers will be used.
Discussion
The discussion is well written. I have no additional comments.
REVIEWER
Sergey Motov Maimonides Medical Center, Brooklyn, NY, USA REVIEW RETURNED 16-Sep-2019
GENERAL COMMENTS
I have read with a great interest your proof-of-concept protocol for relieving acute traumatic pain. I applaud your desire to expand the knowledge about dose -extending placebos in treatment of acute pain and, as a consequence, reduction in opioid prescribing. Your description of the study, methodology, follow up are concise, relevant and practical. However, I have serious concerns about opioid agents that you are proposing in your study, while fully understanding that its an institutional preference. The issue that I have with oxycodone and hydromorphone in your study is that both of this agents are extremely euphorogenic in comparison to oral and parenteral morphine. Euphoria is the driving force of an opioid epidemic and oxycodone and oxycodone-containing analgesics are the main culprit in prescription opioid misuse, diversion, addiction, overdose and death. In your nobel pursuit of safer opioid prescribing practices you failed to acknowledge the importance of qualitative approach to opioids: euphorogenic opioids should not be used in managing acute pain. Furthermore, your full dose group will be receiving 5 mg of oxycodone 6 times a day with total dose of 30 mg which translates into 45 MME. Total daily MME of 50 mg are associated with 2x risks of overdose in comparison to 20 mg MME. Lastly, there is a growing tendencies to limit a number of opioids at discharge from the hospital and 18 tablets over three days seems awful a lot. Your discharge protocols of having oxycodone combined with gabapentin and /or pregabalin are dangerous as both of these agents are known opioid potentiators and concomitant use of which leads to severe respiratory depression. Thus, your current proposed opioid choices and combinations are dangerous and should not be generalized to the rest of the country. I would strongly recommend to revise your current opioid prescribing practices by using highly euphoric and abuse-prone opioids and even consider changing protocols before embarking on the research phase. Additional notes: 1. I did not see what NSAID's and what dose are used in the study.
2. I disagree with excluding non-English speaking patients form the study.
3. I assumed that patients will be given a prescription of oxycodone for no more than 3 days but could not find the exact number of days and tablets. 4. Are the psychological battery testing questionnaire include questions of abuse liability and likeability related to oxycodone use?
VERSION 1 -AUTHOR RESPONSE
Reviewer: 1 Reviewer Name: Cosima Locher Institution and Country: School of Psychology, University of Plymouth UK Please state any competing interests or state 'None declared': None declared Please leave your comments for the authors below The protocol reports on randomized-placebo controlled study called The Relieving Acute Pain (RAP). It is hypothesized that dose-extending placebos can be an effective treatment in patients with any traumatic injuries who take opioids.
In general, the protocol is well written and provides a novel and needed approach, considering the current opioid epidemic.
We thank Dr. Locher for the positive feedback and great suggestions. Please see our answers below.
Abstract:
Introduction
Great catch. Thank you for the suggestion. We reframed the outcomes and hypotheses clarifying that this PoC study will test for feasibility and acceptability rather than efficacy.
We added this hypothesis: "We hypothesize that feasibility and acceptability this method of reducing opioids upon adequate training of the clinical staff and family members."
Clinical Assessments 1. The choice of primary outcomes is reasonable. However, considering the IMMPACT guidelines (e.g., Cooper et al. [2016] . Research design considerations for single-dose analgesic clinical trials in acute pain: IMMPACT recommendations. Pain, 157(2), 288-301), I recommend that emotional distress (and not only functional disability) should be included as an additional outcome. In line with IMMPACT, the so-called "extension code" for pain severity in the new ICD-11 allows to not only measure pain intensity, yet also pain-related interference and pain-related distress) on an NRS scale.
We agreed with the reviewer that the emotional distress associated with pain is a relevant outcome. We added it to the mns including the citations. We will assess emotional distress using the specifiers from Box 1 of the following article: Chronic pain as a symptom or a disease: the IASP Classification of Chronic Pain for the International Classification of Diseases (ICD-11).
Thank you for raising this question. Multitrauma patients will be monitored by a one-by-one nurse and by the Acute Pain Management Service at STC. The rate of opioids used (frequency and dosage) will be documented in both EPIC and in the CRF.
Discussion
The discussion is well written. I have no additional comments. We thank the reviewer for the kind words.
Reviewer: 2 Reviewer Name: Sergey Motov Institution and Country: Maimonides Medical Center, Brooklyn, NY, USA Please state any competing interests or state 'None declared': None declared Please leave your comments for the authors below I have read with a great interest your proof-ofconcept protocol for relieving acute traumatic pain. I applaud your desire to expand the knowledge about dose -extending placebos in treatment of acute pain and, as a consequence, reduction in opioid prescribing.
Your description of the study, methodology, follow up are concise, relevant and practical.
Thank you for the kind words and valuable feedback. Please see our replies to the raised concerns.
However, I have serious concerns about opioid agents that you are proposing in your study, while fully understanding that its an institutional preference. The issue that I have with oxycodone and hydromorphone in your study is that both of this agents are extremely euphorogenic in comparison to oral and parenteral morphine. Euphoria is the driving force of an opioid epidemic and oxycodone and oxycodone-containing analgesics are the main culprit in prescription opioid misuse, diversion, addiction, overdose and death. In your nobel pursuit of safer opioid prescribing practices you failed to acknowledge the importance of qualitative approach to opioids: euphorogenic opioids should not be used in managing acute pain.
Our institution has found that morphine is associated with more side effects than synthetic opioids. Morphine is a non-specific mu receptor agonist that is also associated with histamine release. Therefore anecdotally, patients experienced more side effects including nausea/vomiting, itching, flushing and wheezing in asthmatic patients or patients with COPD. The side effects associated with histamine release frequently required treatment with anti-histamine which contributed to sedation. Therefore, our institution preferentially chooses synthetic opioids that target specific mu receptors related to pain relief and are not associated with histamine release. Although hydromorphone and oxycodone are more potent than morphine, dosage is tailored accordingly.
Overall, we believe that the choice of the opioids is behind the scope of this PoC study protocol. Trauma pain management per se has distinct challenges as compared to other settings (e.g. ED, pre-surgical and post-surgical pain management) Moreover, trials comparing morphine with other opioids from a PK-PD perspective indicate that based on PK-PD characterization of equilibrium delays of opioids, morphine may not be the best option for titration when effects are required immediately (Mackenzie, 2016) . Chang et al (2011)compared hydromorphone versus morphine in patients with acute severe pain presenting to the ED. The difference in change between groups was 1.3 (95% CI = 2.2 to 0.5) but pruritus was higher in the morphine group (6% of patients vs none in the hydromorphone group).
MacKenzie M, Zed PJ, Ensom MH. Opioid Pharmacokinetics-Pharmacodynamics: Clinical Implications in Acute Pain. Management in Trauma. Ann Pharmacother. 2016 Mar; 50(3):209-18. doi: 10.1177/1060028015625659. Chang, AK, Bijur, PE, Gallagher, EJ. Randomized clinical trial comparing the safety and efficacy of a hydromorphone titration protocol to usual care in the management of adult emergency department patients with acute severe pain. Ann Emerg Med. 2011; 58:352-359. This study is designed by and with our clinical teams. For it to be feasible and accepted by both patients and clinical staff, the opioid prescriptions must match the current standard at STC.
Furthermore, your full dose group will be receiving 5 mg of oxycodone 6 times a day with total dose of 30 mg which translates into 45 MME. Total daily MME of 50 mg are associated with 2x risks of overdose in comparison to 20 mg MME.
The patients will be offered oxycodone or placebo as prn. They will only receive 6 doses/day if they need it.
The novelty of this study is that is being done in hospitalized patients with severe acute pain from trauma. All of the enrolled participants will have severe trauma, including multiple long bone fractures, pelvic fractures and thoracoabdominal injuries. 5 mg q 6hrs is on the lower side for our population. As part of our clinical practice, and in this study all patients will be assessed prior to and after every dose by a trained trauma clinician. Patients who do not meet criteria for administration are not given the drug. All of the patients will be in highly monitored settings and are followed by the Acute Pain Management Service (APMS). This study mirrors the current pain management strategies at the enrolling institution and is common in inpatient Trauma Centers.
There are a host of complicated issues in this population including high pain needs and complex treatment options. Hence the need for the proposed feasibility study. There is a patient safety monitoring plan in place.
We chose a dose of MME that is below the CDC recommendation (90 MME per day). If this PoC succeed in terms of feasibility and acceptability we may demonstrate that therapeutic approaches that value non opioid based therapeutics are clinically fine. This will be per se an important shift in current local (and national) attitudes towards acute pain management.
Lastly, there is a growing tendencies to limit a number of opioids at discharge from the hospital and 18 tablets over three days seems awful a lot. Your discharge protocols of having oxycodone combined with gabapentin and /or pregabalin are dangerous as both of these agents are known opioid potentiators and concomitant use of which leads to severe respiratory depression.
We are only focusing on inpatient prescribing. After discussion with the discharging team, we elected to allow the team to follow up with outpatient prescriptions. We will follow up with their requirements after discharge.
Thus, your current proposed opioid choices and combinations are dangerous and should not be generalized to the rest of the country.
The discharge options are managed by the clinicians who treat these multi-trauma patients, we revised the discharge prescriptions from the study protocol to avoid confusion. Those who prescribe treatments for the discharge windows are careful in giving medication that have a safe profile in terms of drug interactions.
I would strongly recommend to revise your current opioid prescribing practices by using highly euphoric and abuse-prone opioids and even consider changing protocols before embarking on the research phase. With respect to this reviewer, the described opioid management is in line with current standards for managing the type of severe pain associated with major trauma in an inpatient setting. It would not be feasible to have the study protocol be different from the common prescribing practices for patients. Both staff and patients would refuse to be involved in a study that resulted in undertreatment of pain.
